Prestige Consumer Healthcare Inc (PBH)

Over the past six months, Prestige Consumer Healthcare's stock price has decreased by 33.61%. Key events impacting the stock include decreased revenue in Fiscal Q1 2026 due to supply constraints for Clear Eyes, surpassing sales and earnings expectations in Fiscal Q2 2026, the acquisition of Pillar5 Pharma, reporting revenue of $283.4 million in Fiscal Q3 2026, the agreement to acquire Breathe Right® and other brands from Foundation Consumer Healthcare for $1.045 billion, price target adjustments by Oppenheimer, and share repurchases.

Demand for Prestige Consumer Healthcare's products exhibits seasonality depending on the product category. Cold and flu product sales peak during colder weather in the winter months. Allergy medication usage and sales typically peak in spring and fall. Younger consumers tend to buy vitamins, minerals, and supplements every one or two months, while older consumers buy quarterly. Gastrointestinal remedies are typically purchased less frequently, often once a year or less.

Prestige Consumer Healthcare, Inc. specializes in developing, manufacturing, marketing, and distributing over-the-counter health and personal care products, focusing on acquiring and revitalizing established brands that hold leadership positions and are recommended by medical professionals. Its product portfolio includes analgesics like BC Powder and Goody's Headache Powder, women's health products like Monistat and Summer's Eve, eye care products like Clear Eyes and TheraTears, oral care products like DenTek, Chloraseptic, Luden's, and Efferdent, dermatological treatments like Compound W and Nix, gastrointestinal remedies like Dramamine, Fleet, Gaviscon, and Beano, pediatric needs products like Boudreaux's Butt Paste and Little Remedies, and other products like Debrox, Nytol, Fess, and Hydralyte.

Prestige Consumer Healthcare operates primarily in North America, specifically the United States and Canada, which accounts for approximately 85% of its total revenue. The company also has a significant international presence, particularly in Australia, and in certain other international markets including New Zealand and select Asian and European regions. Its operations are structured into two main segments: North American OTC Healthcare and International OTC Healthcare.

Prestige Consumer Healthcare's brand reputation is built on acquiring and nurturing established, well-recognized consumer brands, many of which have been around for generations. These brands often enjoy category leadership and are recommended by medical professionals, contributing to consumer trust. A past event that could have affected the company's reputation was a voluntary recall by Medtech Products Inc. of specific lots of Little Remedies® Honey Cough Syrup due to microbial contamination.

Institutional investors hold a substantial majority of Prestige Consumer Healthcare's shares, approximately 84.8% as of early 2025. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., State Street Global Advisors, Inc., Ariel Investments, Llc, Dimensional Fund Advisors LP, Kayne Anderson Rudnick Investment Management Llc, Allspring Global Investments Holdings, LLC, Geode Capital Management, Llc, Delaware Management Holdings, Inc., Morgan Stanley and Goldman Sachs Group Inc. Insider ownership is approximately 0.8% to 1.40%, with David Donnini noted as a significant individual shareholder.